The Kezar Life Sciences covalent immunoproteasome inhibitor, KZR-616, licensed from Onyx, targets the LMP7 and LMP2 active sites of the immunoproteasome, and is currently in Ph. II trials for autoimmune disorders…
Home > KZR-616
this content is exclusive to
Premium members
Unlock this content with a Premium membership to read it now.